These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1851596)
41. Intermittent steroid therapy. Its effect on hypothalamic-pituitary-adrenal function and the response of plasma growth hormone and insulin to stimulation. Martin MM; Gaboardi F; Podolsky S; Raiti S; Calcagno PL N Engl J Med; 1968 Aug; 279(6):273-8. PubMed ID: 4298259 [No Abstract] [Full Text] [Related]
42. Effects of a new glucocorticoid, deflazacort, on pituitary-adrenal function in man: a comparison with prednisone. Criscuolo D; Fraioli F; Bonifacio V; Paolucci D; Isidori A Int J Clin Pharmacol Ther Toxicol; 1980 Jan; 18(1):37-41. PubMed ID: 6245036 [TBL] [Abstract][Full Text] [Related]
43. Corticosteroid secretion: responses to alpha1-24 corticotropin, metyrapone and dexamethasone. Frawley TF Trans Am Clin Climatol Assoc; 1972; 83():45-56. PubMed ID: 4339147 [No Abstract] [Full Text] [Related]
44. Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study. Goebel MU; Czolbe F; Becker H; Janssen OE; Schedlowski M; Limmroth V Eur Neurol; 2005; 53(4):182-7. PubMed ID: 15947464 [TBL] [Abstract][Full Text] [Related]
45. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Annane D; Pastores SM; Rochwerg B; Arlt W; Balk RA; Beishuizen A; Briegel J; Carcillo J; Christ-Crain M; Cooper MS; Marik PE; Umberto Meduri G; Olsen KM; Rodgers S; Russell JA; Van den Berghe G Intensive Care Med; 2017 Dec; 43(12):1751-1763. PubMed ID: 28940011 [TBL] [Abstract][Full Text] [Related]
46. Cortisol levels after single local steroid injection. Maillefert JF; Aho S; Piroth-Chatard C; Tavernier C Am J Med; 1996 May; 100(5):586-7. PubMed ID: 8644775 [No Abstract] [Full Text] [Related]
47. Dexamethasone suppression test predicts later development of an impaired adrenal function after a 14-day course of prednisone in healthy volunteers. Neidert S; Schuetz P; Mueller B; Christ-Crain M Eur J Endocrinol; 2010 May; 162(5):943-9. PubMed ID: 20142368 [TBL] [Abstract][Full Text] [Related]
48. Sense and sensitivity: assessing inhaled corticosteroid effects on the hypothalamic-pituitary-adrenal axis. Allen DB Ann Allergy Asthma Immunol; 2002 Dec; 89(6):537-9. PubMed ID: 12487216 [No Abstract] [Full Text] [Related]
49. [Therapy of multiple sclerosis]. Arasa F Folia Clin Int (Barc); 1969 Jan; 19(1):7-23. PubMed ID: 4308450 [No Abstract] [Full Text] [Related]
50. [Corticoids and multiple sclerosis]. Defer G; Cesaro P; Degos JD Ann Med Interne (Paris); 1994 Jun; 145 Suppl 2():37-41. PubMed ID: 8074340 [No Abstract] [Full Text] [Related]
51. [Extent of hypophyseal-adrenal inhibition after corticosteroid treatment for varying periods. 3. Study of lipolysis and the adrenal response, using the metopirone test in subjects exposed to prolonged steroid therapy]. Olivi O; Genova R; Balli F Clin Pediatr (Bologna); 1968 Sep; 50(9):572-80. PubMed ID: 5728196 [No Abstract] [Full Text] [Related]
52. Hypothalamo-pituitary-adrenal axis testing: nothing is sacred and caution in interpretation is needed. Dickstein G Clin Endocrinol (Oxf); 2001 Jan; 54(1):15-6. PubMed ID: 11167920 [No Abstract] [Full Text] [Related]
53. Adrenocortical response to high dosage ACTH therapy in patients with multiple sclerosis. Alexander L; Cass LJ; Enders M; Sarai K Confin Neurol; 1966; 28(1):1-17. PubMed ID: 4290212 [No Abstract] [Full Text] [Related]
54. Endocrine complications of topical and intralesional corticosteroid therapy. Curtis JA; Cormode E; Laski B; Toole J; Howard N Arch Dis Child; 1982 Mar; 57(3):204-7. PubMed ID: 6462114 [TBL] [Abstract][Full Text] [Related]
55. [The effect of large doses of corticosteroids on stomach ulcer formation: a new hypothesis]. Filaretova LP; Filaretov AA Fiziol Zh SSSR Im I M Sechenova; 1992 Oct; 78(10):77-83. PubMed ID: 1302702 [TBL] [Abstract][Full Text] [Related]
56. [Evaluation of the hypophyseal-hypothalamo-adrenal axis in patients undergoing chronic corticotherapy at suppressive doses]. Gálvez Gudiño VJ Rev Alerg Mex; 1993; 40(5):132-4. PubMed ID: 9312341 [TBL] [Abstract][Full Text] [Related]
57. Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial. Schuetz P; Leuppi JD; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Mueller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J Eur J Endocrinol; 2015 Jul; 173(1):19-27. PubMed ID: 25855628 [TBL] [Abstract][Full Text] [Related]
58. Pituitary-adrenal responsiveness in surgical patients on acute and chronic corticosteroid therapy: plasma corticosterone assay. Newsome HH Surgery; 1973 Aug; 74(2):204-13. PubMed ID: 4352228 [No Abstract] [Full Text] [Related]
59. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Einaudi S; Bertorello N; Masera N; Farinasso L; Barisone E; Rizzari C; Corrias A; Villa A; Riva F; Saracco P; Pastore G Pediatr Blood Cancer; 2008 Mar; 50(3):537-41. PubMed ID: 17828747 [TBL] [Abstract][Full Text] [Related]